A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Active, not recruiting · Phase 1 · NCT07225556
Conditions: Overweight, Obesity
At a glance
- Research payments reported, 2025
- $5,720
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 84
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY4167586 (drug), Placebo (drug), LY4167586 (drug)
- Dates
- Started 2025-11-18; completion 2026-12
- Results posted
- Not yet
The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months.
From ClinicalTrials.gov, last updated 2026-07-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $5,720 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research LP Dallas $5,720
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.